Sarah Romano - 06 Jan 2025 Form 4 Insider Report for Entero Therapeutics, Inc. (ENTO)

Reporting relationship: Chief Financial Officer
Issuer ticker: ENTO
Reported as of: 06 Jan 2025
Net transaction value: -$465
SEC form: 4
Accepted by SEC: 08 Jan 2025, 16:23:52 UTC
Prior SEC filing: 10 Oct 2024
Next SEC filing: 11 Apr 2025
Source filing: View source filing
Reporting owner signature: /s/ Sarah Romano

Key filing fact

Sarah Romano filed Form 4 for Entero Therapeutics, Inc. (ENTO) on 08 Jan 2025.

Key facts

This page summarizes Sarah Romano's Form 4 filing for Entero Therapeutics, Inc. (ENTO).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Jan 2025, 16:23.

Change

Previous filing in this sequence was filed on 10 Oct 2024.
Current net transaction value: -$465.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENTO transaction

Common Stock

Sale

Transaction value: $465
Shares: -727
Change %: -4%
Price: $0.6400
Shares after: 17,287
Date: 06 Jan 2025
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units ("RSUs"). The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.

Footnote F2

Includes unvested RSUs.